Event: 'MAIN EVENT: Shaking The MoneyTree - Venture Capital Trends & Predictions'
Date: Thursday, September 07, 2006 At 06:00
Duration: 2 Hours 30 Minutes
Wilson Sonsini Goodrich & Rosati (WSGR Campus), 950 Page Mill Road, Palo Alto, 94304 Laura Weigant Email: [email protected]
The MoneyTree™ report is the definitive source of information on emerging companies that receive financing and the venture capital firms that provide it. As a collaboration between PricewaterhouseCoopers, Thomson Venture Economics and the National Venture Capital Association, it is the only industry-endorsed research of its kind.
Where’s the money going, and who’s putting it?
PricewaterhouseCoopers will unveil the MoneyTree™ report - a quarterly study of global venture capital investment activity - followed by a lively discussion from top venture capitalists who will explore what they perceive as the key current and future trends in venture financing, for Silicon Valley and Globally.
• What are the hot emerging Markets – consumer, business, geographic, social, entertainment?
• What are the hot emerging technologies – IT, Communications, Mobility, Medical?
• How are these interrelated?
• Who should you approach to fund YOUR idea?
• John Occhipinti, Managing Director, Woodside Fund
• Rich Ferrari, Managing Director, Denovo Ventures
• Craig Taylor, Partner, Alloy Ventures
• Ed Lambert, Senior Vice President, Bridge Bank
• John Lonergan, MachVentures, Life Science Angels
Moderator: Steve Bengston, PricewaterhouseCoopers
Thursday, Sept 7
6.00-7.00 pm: Networking and Dinner
7.00-8:30 pm: Panel discussion and Q/A
To reserve an Exhibit Table
Contact [email protected], $500 Members, $1,000 Non-members.
Wilson Sonsini Goodrich & Rosati (WSGR Campus), 950 Page Mill Road, Palo Alto, 94304
PRE-REGISTERED RATES (All Rates Include Hors D’oeuvres)
Members - $20; Affiliates who advertise this event - $29;General Public - $49
WALK-IN RATES: Add $10.00 to the listed price
Seating is limited, so early registration is recommended to avoid disappointment on the day.
Rich Ferrari, Denovo Ventures
In 1991, Rich became the CEO of Cardiovascular Imaging Systems. As CEO, he orchestrated a successful IPO and ultimately sold the company to Boston Scientific for $125 million. His most recent success, CardioThoracic Systems Inc. (CTSI), the market leader in disposable instruments and systems for beating heart bypass surgery, was acquired by Guidant for $313 million in November of 1999. Rich was a co-founder of CTSI, and as CEO, he led the company to an initial public offering in only 7 months, the fastest of any medical technology company in history.
Following De Novo’s investment in CryoVascular Systems in 2000, Rich joined the initial five-person team as the start-up CEO. He built the company to 22 employees, was instrumental in developing the clinical and product strategies, and hired the executive team. In April 2005, Boston Scientific acquired CryoVascular, Inc.. In 2002, Rich led Paracor Medical, another De Novo portfolio company. He grew Paracor from its initial 4 to 22 employees, refined the product strategy, raised its Series B round, and hired his replacement CEO.
In 1996 he founded Saratoga Ventures, a venture capital partnership that has provided seed financing to several successful companies, including Atrionix, Oratec, Enteric Medical, Trivascular, and Endotex. Oratec, a portfolio company of which Rich was Chairman, went public and was ultimately acquired by Smith & Nephew, and Trivascular, for which Rich served as a board member, was acquired by Boston Scientific in April 2005.
Rich was also the co-founder of Integrated Vascular Systems (which was recently purchased by Abbott) an early stage femoral artery closure company and Angiosense, a needle-free, jet injection, local drug delivery company. Early in his career, Rich held the position of Executive Vice President and General Manager of ADAC Laboratories.
Rich is the recipient of the Mallinckrodt Award for Excellence in Medicine and twice a finalist for the Entrepreneur of the Year Award.
Craig Taylor, Alloy Ventures
Craig C. Taylor has been an active venture capitalist since 1977. He earned a BS (1972) and an MS (1974) in physics from Brown University, and an MBA from Stanford in 1977. He worked in the Office of Technology Licensing at Stanford from 1975 to 1977. He is a director of Adeza Biomedical (NASDAQ:ADZA), Pharmacyclics (NASDAQ:PCYC) and Solexa (NASDAQ:SLXA), all public companies. He serves on the boards of several private companies, including ForteBio, Galileo Pharmaceuticals, K2 Optronics, Labcyte, Optimedica, and Zyomyx. Mr. Taylor is a past member of the Board of Directors of the National Venture Capital Association, and serves on the Board of Advisors of the MIT/Stanford Venture Laboratory.
John Occhipinti, Woodside Fund
John Occhipinti has extensive experience in enterprise software technology, marketing, and sales. As Managing Director of Woodside Fund, John dedicates his expertise to the development of ventures in the enterprise software sector. John serves on the Board of Directors of Borderware (messaging security software), VeriWave (Wireless LAN test equipment), and Tacit Software (Enterprise Expertise Automation software), and is an active board observer at Intalio (business process management software) and Intelligent Markets (financial services software).
Prior to joining Woodside Fund, John was an early executive at Netscape Communications. Initially, John led a team that drove the company’s first significant revenues, helping launch Netscape through its initial public offering. Later, John ran Netscape’s Electronic Software Distribution and Strategic Channel Sales groups. During his tenure at Netscape, John worked closely with hundreds of early stage entrepreneurs helping build web-based e-commerce and enterprise software applications. Prior to Netscape, John worked at Oracle Corporation, marketing and selling large-scale enterprise database technologies.
John has an MBA from the University of California, Berkeley, Walter A. Haas School of Business, and a BA from the University of California Berkeley.
Ed Lambert, Bridge Bank
a resident of San Jose, is a Senior Vice President of the Bank. Ed is a Tech/Life Sciences banking veteran who most recently was with Comerica Bank as Senior Vice President, Business Development in their Tech/Like Sciences Division. His responsibility focused on maintaining and expanding profitable relationships with Emerging Growth to Public High-Tech and Life Science Companies. Results led to a historical seven-figure Annual Net Profit to the Bank. He contributes his success to being an overall "solution source" partner to clients, prospects, referral partners and colleagues - for any problem.
Mr. Lambert began his 24 years of banking/lending experience with Bank of America. He enjoyed successful years with Silicon Valley Bank and Imperial Bank, which several years ago was acquired by Comerica Bank. Ed also began the Tech Practice for Coast Business Credit, building to $20-30MM in annual commitments. Ed is a graduate of Santa Clara University with an MBA, and holds a BA in history from the University of California at Santa Cruz.
Ed is an 18-year member of the Churchill Club and currently sits on the executive committee of the American Electronics Association.
John Lonergan, Mach Ventures
John Lonergan, Managing General Partner of MachVentures, brings more than 20 years of industry experience
in the fields of diagnostics, medical technology and software. MachVentures focuses on early-stage medical
devices in the Bay Area, bringing clinical, engineering and management expertise to all phases of a product’s
development. The venture fund focuses on minimally-invasive devices in vascular medicine, orthopedics,
interventional pulmonology and aesthetics. Mr. Lonergan has founded two biotech companies based on
technologies developed at Los Alamos National Laboratories and the University of California at San Diego. He
co-founded Bio-Star Private Equity Fund in 2003 with Dr. Louis Cannon, raising $30 million and making ten
investments in early-stage medical device companies in less than two years. In 1999, he co-founded CardioNow, a company which provides cardiology networks and services to hospitals and medical device companies. CardioNow’s customers include Johnson & Johnson, Boston Scientific, Guidant, Abbott and hospitals throughout the United States. CardioNow was sold in early 2004 to Heartlab, the number one supplier of cardiac networks to hospitals. Prior to co-founding CardioNow, Mr. Lonergan led European divisions of Dade International, a $1.3 billion diagnostics company, managing Germany, France, and the Benelux. He took responsibility for Boston Scientific’s European interventional cardiology division, growing sales to $177 million and regaining Boston’s number one position in stents in this hotly competitive marketplace. Mr. Lonergan is a 1976 graduate of Harvard Business School and a former McKinsey consultant
Added by svaseinfo on August 5, 2006